Guillaume Roberge
@GuillaumeRobMD
Spécialiste en médecine interne générale, CHU de Québec, Hôpital Saint-François d'Assise Thrombosis fellowship 2019-2020 - The Ottawa Hospital, DRCPSC
You might like
💉 New in @AjHematology - The WAVe Study 🩸 In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing. 📖 Read: doi.org/10.1002/ajh.70…
The authors of a new review describe the current state of the evidence informing clinical practice for the treatment of type B aortic dissection, as well as areas of controversy and future directions. Learn more: nej.md/4mKYgcb
In patients with heparin-induced thrombocytopenia, pathogenic antibodies were found to be monoclonal, which challenges previous views of HIT as a polyclonal disorder and suggests new avenues for diagnosis and treatment. Full study results: nej.md/4pkaYAq
📢 New in @NEJM: In patients with provoked VTE + enduring risk factors, extended low-dose apixaban (2.5 mg bid ×12 months) 🔒 reduced recurrent VTE risk by nearly 90% (1.3% vs 10.0%) 👉 HR 0.13 🩸 Major bleeding was rare (1 pt). 👉 nejm.org/doi/full/10.10…
Lp(a) ⬆️the risk of ASCVD, but how about #VTE??🤔 🚨We summarize the existing pathophys & epidemiological data in @TH_Journal w an 👁️toward findings from #RCTs: thieme-connect.com/products/ejour… Great work #MarianaPfeferman🙏🙏 to 🌟team! #Cardiology #Lipids
Anti-PF4 disorders: Pathogenesis, diagnosis and treatment buff.ly/hlPEh30
🧠 Diagnosing recurrent VTE is challenging. PREDICTORS study (n=723) showed that existing clinical decision rules (CDRs) identify patients at higher risk and RO recurrence without imaging in ~15% 📊 In low/moderate-risk PE with negative D-dimer: 🟢 0/82 recurrent VTE (0%; 95% CI…
Along with collaborators at @UTSWMedCenter we report a study in the @NEJM on the potential role of monoclonal anti-PF4 abs in recurrent miscarriage. Larger studies to follow! @MayoClinic @mayocliniclabs nejm.org/doi/full/10.10…
We have an ISTH special on CLOT Conversations with 7 episodes featuring interviews with a range of presenters from the conference. The episodes include potentially practice-changing information from Dr Lana Castellucci on the COBRA trial and from Dr Gregoire Le Gal on the…
🩸 WaVE Study Alert! In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective. 🔹 Anti-Xa levels aligned with non-obese patients 🔹 Higher levels seen in those with bleeding Important data to guide dosing in CAT & obesity.…
Implementation matters! A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸📉
🚨 SPECTACULAR RCT at #ISTH2025! Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk ✅ Supporting the safety of ruling out PE with a SPECT-based algorithm SPECTacular findings indeed! 🫁💥
Diminution (50%) du risque de syndrome post-thrombotique modéré à sévère avec l’apixaban comparativement au coumadin, particulièrement chez les patients obèses. Étude observationnelle. #isth2025
Une dose réduite d' AOD en prévention secondaire de TEV chez les patients avec IMC > 30 est associée à un risque augmenté de récidive de thromboembolie veineuse sans diminution du risque de saignement, et une hausse du risque des thromboses artérielles. #ISTH2025
Diminution potentielle du risque de thromboembolie veineuse avec les agonises du GLP1 comparativement à d’autres médications pour la perte de poids. Étude rétrospective. #ISTH2025
D-dimères ajustés pour l’âge à appliquer dans la stratégie diagnostique des TVP. Étude Adjust-DVT #ISTH2025
L’impact de reclassifier les patients SAPL selon les critères de 2023, qui répondaient aux critères de 2006, est incertain, surtout chez les SAPL obstétricals. #ISTH2025
Une nouvelle stratégie diagnostique pour l’embolie pulmonaire chez les patients avec MPOC. #ISTH2025 Par @Vicky_Mai_
United States Trends
- 1. Araujo 180K posts
- 2. Chelsea 627K posts
- 3. Barca 251K posts
- 4. Estevao 253K posts
- 5. Barcelona 450K posts
- 6. Ferran 76.9K posts
- 7. Yamal 194K posts
- 8. Oklahoma State 4,609 posts
- 9. Eric Morris 3,055 posts
- 10. Cucurella 98.6K posts
- 11. Godzilla 25.3K posts
- 12. Rashford 24.3K posts
- 13. Flick 48.3K posts
- 14. Kounde 48.3K posts
- 15. Enzo 69K posts
- 16. Pedri 52.6K posts
- 17. #CHEBAR 16.8K posts
- 18. Skippy 4,667 posts
- 19. Raising Arizona 1,765 posts
- 20. Cooks 12.1K posts
Something went wrong.
Something went wrong.